Skip to content
DataLookout
Menu

BCTOP-T-N01NCT05999149

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)

StatusRecruiting
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date changed from estimate of Aug 30, 2025 to May 30, 2026
    • Eligibility criteria expanded, about 2 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Sep 1, 2023 to Aug 20, 2023
    • Study title revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Pathological complete response (pCR) rate
Timeframe: Up to approximately 24 weeks

Secondary (5)

Event-free Survival (EFS) as assessed by Investigator
Disease-free Survival (DFS) as assessed by Investigator
Distant Disease-free Survival (DDFS) as assessed by Investigator
Objective response rate (ORR) in accordance with RECIST v1.1
Number of responders Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) for target lesions assessed by MRI.

Arms and interventions

Arm AExperimental

Camrelizumab Plus Chemotherapy and Famitinib

Arm BActive comparator

Camrelizumab Plus Chemotherapy

Drugs: Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy

Sites

2 sites in 1 country